CTLA4 and neoplasm: In particular, immune checkpoint inhibitors (ICIs) that target the programmed death-ligand 1 (PD-L1), programmed death 1 (PD-1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) pathways can restore T-cell functionality and promote anti-tumor immunity (1).